---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-25-000048"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:05:28.940350+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xencor reports positive interim Phase 1 results for XmAb942; half-life >71 days

## Summary
- XmAb942 well tolerated; no serious AEs, no discontinuations.
- Half-life >71 days supports 12-week maintenance dosing in planned Phase 2b UC study.
- Phase 2b XENITH-UC trial in moderate-to-severely active UC expected to start H2 2025 (n~220).
- TL1A x IL23p19 bispecific lead selection on track; FIH study planned for 2026.
- Company to host call at 5pm ET today.

## SEC filing metadata
- accession: 0001326732-25-000048
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000048/0001326732-25-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000048/xncr-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-25-000048
- JSON: https://secwatch.observer/filing/0001326732-25-000048.json
- Plain text: https://secwatch.observer/filing/0001326732-25-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.